�������ý

ACP does not support “Diabetes Monitoring for People With Diabetes and Schizophrenia” for application at the health plan level because of uncertain validity. Not all patients require LDL testing as frequently as the performance measure specifies. The USPSTF recommends screening women aged 45 years and older if they are at increased risk for coronary heart disease and women aged 20- 45 years if they are at risk for coronary heart disease. Additionally, guidelines recommend that patients with diabetes between the ages of 40 to 75 receive a statin regardless of LDL-C levels. As a result, this performance measure could promote the overuse of LDL-C testing. Developers should consider separating the numerator into two discrete performance measures: testing for HbA1c and testing for LDL. The specifications should add exclusion criteria for patients currently prescribed statin therapy and patient refusal. CBE 1934 is appropriate to assess the performance of health plans covering a significant proportion of patients who are diagnosed with mental illness. Health plans can quickly obtain detailed clinical management data from various information systems (e.g., claims, EHRs, pharmacy), but physicians are not privy to the same information.